Understanding Light Chain Amyloidosis | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Patient Education

Understanding Light Chain Amyloidosis

key information

source: ASH Clinical News

year: 2016

summary/abstract:

Amyloidosis refers to several different types of diseases where abnormal proteins are produced. These protein fibers can attach and deposit into organs, tissues, nerves, and other places in the body, which affects normal function of the area. As the amyloid protein increases, health problems and organ damage may occur. When amyloid clusters gather, they can travel to several places throughout the body (systemic) or remain confined in one specific area (localized). The various types of amyloidosis have different treatment courses; therefore, the correct diagnosis is extremely important.
 
Understanding Light Chain Amyloidosis
In the United States, light chain, or AL, amyloidosis is the most common type, with approximately 4,500 new cases diagnosed each year. It usually affects individuals between 50 and 80 years old. AL amyloidosis is caused by a bone marrow disorder. The marrow in the center of bones produces cells in the blood system, including plasma cells. In AL amyloidosis, these plasma cells produce an abnormal antibody, immunoglobulin protein.
 
read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close